类固醇激素、β2受体激动剂治疗ACOS的临床疗效(短期)分析

Clinical Efficacy(Short-term) Analysis of Steroid Hormone and β2 Receptor Agonist in the Treatment of Asthma-obstructive Pulmonary Disease Overlap Syndrome

目的采取糖皮质激素、β2受体激动剂治疗ACOS,并观察其临床疗效。方法选取2016年1月—2017年12月到我院进行治疗的64例COPD患者以及34例ACOS患者,所有患者均使用糖皮质激素、β2受体激动剂治疗,对比两组患者肺功能及m MRC评分。结果 ACOS组FEV_1、FVC指标改善情况优于COPD组,存在明显差异(P<0.05),且轻-中度气流受限,ACOS组改善更加明显,优于COPD组,但重-极重度气流受限改善情况无明显差异。结论类固醇激素、β2受体激动剂治疗ACOS效果优于COPD,且对轻-中度患者疗效更加显著,早期应用能够改善患者肺功能及临床症状,提升治疗效果。

Objective To take glucocorticoid,β2 receptor agonist treatment of ACOS,and observe its clinical efficacy.Methods Sixty-four patients with COPD and 34 patients with ACOS who were treated in our hospital from January 2016 to December 2017 were enrolled.All patients were treated with glucocorticoid andβ2 receptor agonist.The lung function and m MRC score of two groups were compared.Results In ACOS group,the improvement of FEV1,FVC indicators were better than the COPD group,there was a significant difference(P<0.05).And light-moderate airflow limitation,ACOS group improved more significantly,which was better than COPD group,but there were no significant difference in heavy-to-heavy airflow restriction improvement.Conclusion Steroid hormone,β2 receptor agonist treatment of ACOS better than COPD,and the effect of mild to moderate patients even more significant.